Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interferon receptors are a family of cell-surface receptors that mediate the effects of interferons—potent cytokines central to antiviral defense and immune modulation. There are two main classes relevant to human immunity: Type I interferon receptors consist primarily of the heterodimeric complex formed by IFNAR1 and IFNAR2, which bind all type I interferons including multiple subtypes such as IFN-alpha and IFN-beta. Upon ligand binding, these receptors activate associated Janus kinases (JAK1, TYK2) that phosphorylate signal transducers (STAT1, STAT2) leading to the formation and nuclear translocation of the ISGF3 transcriptional complex. This results in upregulation or repression of hundreds of genes involved in antiviral responses, apoptosis regulation, cell proliferation control, and immunomodulation. The pathway also cross-talks with MAPK and PI3K-Akt signaling cascades for broader cellular effects[1][2][5]. Type II interferon receptors comprise a different heterodimeric structure (IFNGR1/CD119 plus IFNGR2) specific for binding interferon gamma (IFNG). Ligand engagement activates JAK1/JAK2 kinases resulting mainly in phosphorylation/homodimerization/nuclear importation by STAT1; this drives expression from GAS elements on target gene promoters—key for macrophage activation, antigen presentation enhancement, Th1 differentiation support, NK cell activity boosting—and can have both anti-tumorigenic/cytostatic as well as context-dependent pro-tumorigenic effects[4]. Both types play essential roles in host defense against pathogens but can be dysregulated in autoimmunity or cancer.
Activation of JAK/STAT signaling pathway upon ligand binding[2][3][5][7] - Induction of ISGF3 complex formation and nuclear translocation for gene expression regulation - Phosphorylation and dimerization of STAT proteins leading to transcriptional activation or repression of immune genes
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interferon receptor (IFNAR (for type I), IFNGR (for type II)).